Changes in lipid peroxidation induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridinium in mouse brain homogenates.
We studied the effect of the Parkinson-inducing drug 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and of its metabolite 1-methyl-4-phenylpyridinium (MPP+) on lipid peroxidation in mouse brain homogenates in vitro. MPTP (0.35-1.4 mM) inhibited both spontaneous and Fe2+-induced peroxidation in a dose-dependent manner. MPP+, on the other hand, produced a slight enhancement of lipid peroxidation at 1.4 and 2.1 mM concentrations. These results are discussed in terms of the possible mechanisms of MPTP and MPP+ neurotoxicity.
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D015655:1-Methyl-4-phenylpyridinium; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D004347:Drug Interactions; D005296:Ferrous Compounds / Q000008:administration & dosage; D008054:Lipid Peroxides / Q000096:biosynthesis*; D008297:Male; D051379:Mice; D011725:Pyridines / Q000008:administration & dosage / Q000494:pharmacology*; D011726:Pyridinium Compounds / Q000008:administration & dosage / Q000494:pharmacology*
D005296:Ferrous Compounds; D008054:Lipid Peroxides; D011725:Pyridines; D011726:Pyridinium Compounds; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D015655:1-Methyl-4-phenylpyridinium